Related references
Note: Only part of the references are listed.Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer A Systematic Review and Meta-analysis
Eric J. Lehrer et al.
JAMA ONCOLOGY (2021)
De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
Debu Tripathy et al.
ONCOLOGIST (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
R. K. Murthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
David A. Palma et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Divergent evolution of overall survival across metastatic breast cancer (MBC) subtypes in the nationwide ESME real life cohort 2008-2016
S. Delaloge et al.
ANNALS OF ONCOLOGY (2020)
Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy
Yao Wong et al.
ONCOLOGIST (2019)
Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?
T. G. Steenbruggen et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis
Naoki Niikura et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy
Henry M. Kuerer et al.
ANNALS OF SURGERY (2018)
Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed
Wendie D. den Brok et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Complete remission in metastatic breast cancer: expecting the unexpected-results of a cross-sectional study
Giulia Galli et al.
BREAST CANCER (2017)
376PLONG-TERM OUTCOME OF PATIENTS (PTS) WITH HER2-POSITIVE (HER2+) METASTATIC BREAST CANCER (MBC) WHO ACHIEVED A COMPLETE RESPONSE (CR) AFTER ANTIHER2 THERAPY (HER2TX)
G. Gullo et al.
ANNALS OF ONCOLOGY (2017)
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study
Matteo Lambertini et al.
CLINICAL BREAST CANCER (2017)
Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer
K. Harano et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab
Hannah Dzimitrowicz et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Circulating tumor cells in breast cancer
Francois-Clement Bidard et al.
MOLECULAR ONCOLOGY (2016)
Surgical Management of de novo Stage IV Breast Cancer
Seema Ahsan Khan
SEMINARS IN RADIATION ONCOLOGY (2016)
Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
D. J. A. Lobbezoo et al.
BRITISH JOURNAL OF CANCER (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature
Isabel Ihnenfeld Arcienega et al.
TARGETED ONCOLOGY (2015)
Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer - results from the HER-OS patient registry
Isabell Witzel et al.
BMC CANCER (2014)
Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy
Valentina Rossi et al.
BREAST (2014)
Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: Impact of institutions
Frederic Fiteni et al.
BREAST (2014)
Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
D. A. Yardley et al.
BRITISH JOURNAL OF CANCER (2014)
Effect of Adjuvant/Neoadjuvant Trastuzumab on Clinical Outcomes in Patients With HER2-Positive Metastatic Breast Cancer
Rashmi K. Murthy et al.
CANCER (2014)
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Sharon H. Giordano et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Use and Duration of Chemotherapy in Patients With Metastatic Breast Cancer According to Tumor Subtype and Line of Therapy
Davinia S. E. Seah et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2014)
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah-Jane Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Cardoso et al.
ANNALS OF ONCOLOGY (2012)
Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer
G. Gullo et al.
ANNALS OF ONCOLOGY (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review
Tadashi Kobayashi et al.
BREAST CANCER (2012)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review
Shaheenah Dawood et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?
Olivia Pagani et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
The impact of new chemotherapeutic and agents on survival in a population-based of women with metastatic breast cancer hormone cohort
Stephen K. Chia et al.
CANCER (2007)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Is breast cancer survival improving? Trends in survival for patients with recurrent breast cancer diagnosed from 1974 through 2000
SH Giordano et al.
CANCER (2004)
A role for curative surgery in the treatment of selected patients with metastatic breast cancer
SE Singletary et al.
ONCOLOGIST (2003)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
